<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3941">
  <stage>Registered</stage>
  <submitdate>29/08/2012</submitdate>
  <approvaldate>29/08/2012</approvaldate>
  <nctid>NCT01677052</nctid>
  <trial_identification>
    <studytitle>THERMOCOOL® SMARTTOUCH Registry</studytitle>
    <scientifictitle>THERMOCOOL® SMARTTOUCH Catheter for the Treatment of Symptomatic Atrial Fibrillation- Registry</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>STR-148</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Symptomatic Atrial Fibrillation</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions />
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Acute Success - Confirmation of entrance block in the pulmonary veins (acute success)</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Contact Force - Contact force during ablation procedures</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Adverse Events - Procedural complications and adverse events throughout the registry</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subjects with symptomatic atrial fibrillation (AF) who, in the opinion of the
             investigator, are candidates for ablation for atrial fibrillation. Candidates who have
             had previous ablation procedures may be included in the registry

          -  Subjects who have failed at least one antiarrhythmic drug (AAD)(class I or III, or AV
             nodal blocking agents such as beta blockers and calcium channel blockers) as evidenced
             by recurrent symptomatic atrial fibrillation, or intolerable to the AAD.

          -  Subjects must be 18 years of age or older

          -  Subjects must be able and willing to comply with all pre-, post and follow-up testing
             and requirements

          -  Subjects must provide written informed consent to participate in the registry</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Significant congenital anomaly or a medical problem that in the opinion of the
             investigator would preclude enrollment in this registry

          -  History of blood clotting or bleeding abnormalities or contraindication to
             anticoagulation (heparin, warfarin, or dabigatran)

          -  History of a documented thromboembolic event within the past year

          -  Significant pulmonary disease (eg, restrictive pulmonary disease, constrictive or
             chronic obstructive pulmonary disease)or any other disease or malfunction of the lungs
             or respiratory system that produces chronic symptoms

          -  Previous cardiac surgery (eg, CABG) or valvular cardiac surgical procedure (eg,
             ventriculotomy, atriotomy, valve repair or replacement, presence of a prosthetic
             valve)

          -  Awaiting cardiac transplantation or other cardiac surgery within the next 360 days (12
             months)

          -  Diagnosed atrial myxoma

          -  Unstable angina

          -  Uncontrolled heart failure Uncontrolled heart Failure or NYHA Class III or IV heart
             failure

          -  Acute illness, active systemic infection, or sepsis

          -  Any other disease or malfunction that would preclude treatment with ablation in the
             opinion of the investigator</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>426</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC</recruitmentstate>
    <hospital>University of Adelaide/Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Melbourne Health/Royal Melbourne Hospital - Parkville</hospital>
    <hospital>St. Andrew's Hospital - Adelaide</hospital>
    <hospital>The Prince Charles Hospital - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3050 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Aalst</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Genk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Le Chesnay</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villeurbanne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Neustadt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Acquaviva delle Fonti</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Cirie (TO)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lecco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Massa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Monaco</country>
      <state>Monte Carlo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bournemouth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bristol</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cambridge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leicester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Biosense Webster, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of this registry is to obtain "real world" clinical use of contact force
      measurements during ablation procedures.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01677052</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>